The PET tracer [ 11 C]MODAG-005 targets alpha-synuclein aggregates in the brain
Science Translational Medicine · 2026
DOI: 10.1126/scitranslmed.aec0813 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Translational Medicine, 2026. Verfasst von Ran Sing Saw und 28 weiteren Autor:innen. Beteiligte Einrichtung: Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, University of Tuebingen, 72076 Tuebingen, Germany. Hauptthemen laut MEDLINE: alpha-Synuclein, Positron-Emission Tomography, Brain, Carbon Radioisotopes. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 52 Literaturangaben. Gefördert von: Carl-Zeiss-Stiftung, Deutsche Forschungsgemeinschaft, European Union’s Horizon 2020 Research and Innovative Programme.
Abstract (Originalsprache)
Synucleinopathies are neurodegenerative diseases characterized by the presence of brain inclusions containing the pathologically aggregated protein α-synuclein. The development of a positron emission tomography tracer to detect aggregates of misfolded α-synuclein could revolutionize early diagnosis, disease monitoring, and the evaluation of therapeutic efficacy. Here, we present the development, preclinical validation, and first-in-human evaluation of [ 11 C]MODAG-005. In vitro binding experiments demonstrated subnanomolar binding affinity to recombinant α-synuclein fibrils and to α-synuclein inclusions in human brain tissue. Specific binding in multiple system atrophy (MSA) brain tissue was detected using autoradiography and microautoradiography and was validated through immunostaining. In vivo, [ 11 C]MODAG-005 showed good brain penetration, rapid clearance from brain tissue, and low metabolite formation in rodents and nonhuman primates. In addition, a pronounced binding and a good signal-to-noise ratio were achieved in an α-synuclein fibril–injected rat model and in an α-synuclein (A30P) transgenic mouse model in correlation to the pathological load. To validate the potential of [ 11 C]MODAG-005 for therapeutic development, we showed target engagement of the drug candidate anle138b in the brain tissues from α-synuclein (A30P) mice and patients with multiple system atrophy as well as in vivo in α-synuclein fibril–injected rats. Last, first-in-human imaging demonstrated [ 11 C]MODAG-005 binding in brain regions affected by α-synuclein pathology in patients with clinically established MSA cerebellar type, MSA cerebellar and parkinsonian type, and Parkinson’s disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, University of Tuebingen, 72076 Tuebingen, Germany.
- MODAG GmbH, 55234 Wendelsheim, Germany.
- Department of NMR-based Structural Biology, Max Planck Institute for Multidisciplinary Sciences, 37077 Goettingen, Germany.
- Department of Neurology, Eberhard Karls University Tuebingen, 72076 Tuebingen, Germany.
- Hertie Institute for Clinical Brain Research, Department of Neurodegenerative Diseases, Eberhard Karls University Tuebingen, 72076 Tuebingen, Germany.
- German Center for Neurodegenerative Diseases, 72076 Tuebingen, Germany.
ORCID-Profile: Ran Sing Saw, Felix Schmidt, Andrei Leonov, Daniel Bleher, Ann-Kathrin Grotegerd, Benjamin Roeben, Fabian Schmidt, Matthias Reimold, Viktoria C Ruf, Christine M Sandiego, Kelly E Henry, Martin Schaller, Philipp J Kahle, Johannes Levin, Thomas Gasser, Kathrin Brockmann, Gerald Reischl, Christian la Fougère, Bernd J Pichler, Andreas Maurer, Christian Griesinger, Armin Giese, Kristina Herfert
Förderung
- Carl-Zeiss-Stiftung
- Deutsche Forschungsgemeinschaft
- European Union’s Horizon 2020 Research and Innovative Programme
- Michael J Fox Foundation for Parkinson’s Research
- MODAG GmbH
- Max Planck Society
Zitieren
APA
Saw, R. S., Haas, S., Schmidt, F., Ryazanov, S., Leonov, A., Bleher, D., Grotegerd, A. K., Kuebler, L., Roeben, B., Schmidt, F., Reimold, M., Bonanno, F., Ruf, V. C., Dahl, B., Sandiego, C. M., Henry, K. E., Papadopoulos, I., Schaller, M., Kahle, P. J., …, & Herfert, K. (2026). The PET tracer [ 11 C]MODAG-005 targets alpha-synuclein aggregates in the brain. Science Translational Medicine. https://doi.org/10.1126/scitranslmed.aec0813
Vancouver
Saw RS, Haas S, Schmidt F, Ryazanov S, Leonov A, Bleher D, et al. The PET tracer [ 11 C]MODAG-005 targets alpha-synuclein aggregates in the brain. Science Translational Medicine. 2026. doi:10.1126/scitranslmed.aec0813
BibTeX
@article{Saw2026,
author = {Saw, Ran Sing and Haas, Sabrina and Schmidt, Felix and Ryazanov, Sergey and Leonov, Andrei and Bleher, Daniel and Grotegerd, Ann-Kathrin and Kuebler, Laura and Roeben, Benjamin and Schmidt, Fabian and Reimold, Matthias and Bonanno, Federica and Ruf, Viktoria C and Dahl, Bernadette and Sandiego, Christine M and Henry, Kelly E and Papadopoulos, Ioannis and Schaller, Martin and Kahle, Philipp J and Levin, Johannes and Gasser, Thomas and Brockmann, Kathrin and Reischl, Gerald and la Fougère, Christian and Pichler, Bernd J and Maurer, Andreas and Griesinger, Christian and Giese, Armin and Herfert, Kristina},
title = {The PET tracer [ 11 C]MODAG-005 targets alpha-synuclein aggregates in the brain},
journal = {Science Translational Medicine},
year = {2026},
doi = {10.1126/scitranslmed.aec0813}
}
EUVIMED